Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

CC49 is a "second generation" monoclonal antibody to B72.3, which reacts with the pancarcinoma antigen TAG-72. CC49 has been shown to efficiently target human colon carcinoma xenografts and is currently being evaluated in both diagnostic and therapeutic clinical trials. We describe here the construction and characterization of a recombinant single-chain Fv (sFv) of CC49. The sFv was shown to be a Mr 27,000 homogeneous entity which could be efficiently radiolabeled with 125I or 131I. Comparative direct binding studies and competition radioimmunoassays using CC49 intact IgG, F(ab')2, Fab', and sFv revealed that the monomeric CC49 Fab' and sFv had relative binding affinities 8-fold lower than the dimeric F(ab')2 and intact IgG. Nonetheless, the 131I-labeled sFv was shown to bind biopsies of TAG-72-expressing tumors. Metabolism studies in mice, using radiolabeled CC49 IgG, F(ab')2, Fab', and sFv, demonstrated an extremely rapid plasma and whole body clearance for the sFv. CC49 sFv plasma pharmacokinetic studies in rhesus monkeys also showed a very rapid plasma clearance (T1/2 alpha of 3.9 min and T1/2 beta of 4.2 h). Tumor targeting studies with all four radiolabeled Ig CC49 forms, using the LS-174T human colon carcinoma xenograft model, revealed a much lower percentage injected dose/g tumor binding for the CC49 monomeric sFv and Fab' as compared to the dimeric F(ab')2 and intact IgG. However, tumor:normal tissue ratios (radiolocalization indices) for the sFv were comparable to or greater than those of the other Ig forms. High kidney uptake with 125I-labeled Fab' and F(ab')2 was not seen with 125I-sFv. Gamma scanning studies also showed that 131I-CC49 sFv could efficiently localize tumors. The CC49 sFv may thus have utility in diagnostic and perhaps therapeutic applications for a range of human carcinomas.

[1]  I. Pastan,et al.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[3]  J. Schlom,et al.  Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. , 1989, Surgery, gynecology & obstetrics.

[4]  R. Salem,et al.  Detection of the tumor-associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon. , 1989, Journal of the National Cancer Institute.

[5]  R. Paxton,et al.  Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin supergene family. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Schlom,et al.  A radioimmunoassay for the detection of a human tumor‐associated glycoprotein (tag‐72) using monoclonal antibody B72.3 , 1986, International journal of cancer.

[7]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[8]  T. Waldmann,et al.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin , 1989, Nature.

[9]  P. Hand,et al.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Schlom,et al.  Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. , 1988, Cancer research.

[11]  K. D. Hardman,et al.  In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.

[12]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Schlom,et al.  Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors , 1987, Diseases of the colon and rectum.

[14]  J. Schlom,et al.  Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. , 1990, Cancer research.

[15]  I. Pastan,et al.  Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv) , 1991, Molecular and cellular biology.

[16]  P. Hand,et al.  Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. , 1983, Cancer research.

[17]  H. Kitagawa,et al.  A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAc alpha(2----6)GalNAc, in mucin-type glycoproteins. , 1988, The Journal of biological chemistry.

[18]  S. Aaronson,et al.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. , 1973, Journal of the National Cancer Institute.

[19]  M. Kuroki,et al.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. , 1988, Cancer research.

[20]  R. Glockshuber,et al.  A comparison of strategies to stabilize immunoglobulin Fv-fragments. , 1990, Biochemistry.

[21]  L. Mansi,et al.  A prospective imaging study of 131I‐B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report , 1988, Nuclear medicine communications.

[22]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[23]  S. Larson,et al.  Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3 , 1987, International journal of cancer.

[24]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[25]  J. Schlom,et al.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. , 1986, Cancer research.

[26]  W. Gerhard,et al.  The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus. , 1979, Molecular immunology.

[27]  M. Herlyn,et al.  The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution. , 1989, The American journal of pathology.

[28]  A. Thor,et al.  Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. , 1990, Cancer research.

[29]  F. Eckstein,et al.  Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis. , 1986, Nucleic acids research.

[30]  F. Real,et al.  Expression of tag‐72 in normal colon, transitional mucosa, and colon cancer , 1989, International journal of cancer.

[31]  I. Pastan,et al.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Schlom,et al.  Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. , 1988, Cancer research.